Previous Article | Next Article ![]()
Journal of Clinical Microbiology, 05 1997, 1199-1202, Vol 35, No. 5
M Abele-Horn, C Wolff, P Dressel, F Pfaff and A Zimmermann
In this prospective study, the prevalence of the two Ureaplasma urealyticum
biovars, parvo and T960, was determined in pregnant women and in
gynecological patients colonized by ureaplasmas. Furthermore, we
investigated the association of these biovars with gynecological
complications and adverse pregnancy outcome. Isolates of U. urealyticum
from 254 women were biotyped by a PCR method recently developed. The parvo
biovar was found in 81% (206 of 254) of the patients, and the T960 biovar
was found in 30% (76 of 254) of the patients; 6% (14 of 254) of the women
were coinfected. Identical biovars were detected in mothers and their
infants. Serial isolations or cultures from different sampling sites of the
same individual revealed the same biovar. T960 was dominant in patients
with pelvic inflammatory disease (57%) and patients who had had a
miscarriage (42%), showed a higher rate of tetracycline resistance than did
parvo isolates (55 versus 18%), and seemed to have more adverse effects on
pregnancy outcome with regard to birth weight (2,500 versus 1,720 g),
gestational age (35 versus 30 weeks), and preterm delivery (35 versus 77%).
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease
Max von Pettenkofer Institute, Ludwig Maximilian University, Munich, Germany.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|